GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

The growth of these products comes from strong patient demand. These two long-acting medicines contributed more than 50% of the total HIV growth and now account for 20% of HIV sales. In 2025, GSK ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

The GSK oncology products it has sold on to Novartis were worth approximately $2 billion in 2014, having posted a growth of around 32 per cent compared to the previous year. The drugs include ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK's revenue and EPS exceeded my expectations ... part of the dolutegravir products in the chart below. Let's dive into the reasons for Dovato's sales growth, which totaled $813 million, up ...

This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

GlaxoSmithKline Limited (GSK) in Kenya has officially changed its legal entity name to Haleon Kenya Limited. Haleon ...